Loading
WH
Wuhan Hiteck Biological Pharma Co.,Ltd Stock: price and insider trades · China
海特生物
Wuhan Hiteck Biological Pharma Co.,Ltd: what insiders have been doing
Every trade that managers of Wuhan Hiteck Biological Pharma Co.,Ltd disclose to SSE / SZSE (CSRC) is tracked on this page. The company sits in the Health Care sector. No insider at Wuhan Hiteck Biological Pharma Co.,Ltd has published a filing in the past twelve months. The most recent one dates from 23 December 2021.
Over the whole record (from 2021), the tally stands at no purchases and 2 sales.
In the same sector, recent insider purchases at MAIA Biotechnology, Inc. and Cooper Companies, Inc. also feature in our signals. These figures are compiled from regulatory filings published by SSE / SZSE (CSRC). They describe what insiders did and are not a recommendation.
Insider Decl.
2
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
€965,140
2 ops. · all time
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 22,900 of 26,330 companies
24.8
score / 100
Value22
Quality28
FCF yld-4.1%
Earn yld-7.5%
EV/EBITDA·
ROE-12%
Gross mgn43%
Net mgn-43%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
CN¥24.62
Analyst consensus
Income statement
RevenueCN¥541.4M
Gross profitCN¥230.9M43% margin
EBITDA-CN¥140M-26% margin
Net income-CN¥231.3M-55.1% margin
Valuation
P/Book1.5x
Beta-0.30
Balance sheet & cash
Market capCN¥3.2B
Total debtCN¥71M
Free Cash Flow-CN¥127.1M
Debt / Equity1%
Profitability & ownership
ROE-12.4%
ROA-4.4%
% insiders45.5%
% institutions0.9%
Last declaration on 23 December 2021
About Wuhan Hiteck Biological Pharma Co.,Ltd
海特生物 is a company focused on the health and pharmaceutical sector, specializing in the development of biopharmaceutical products. It is listed on the XSHE market.
